Clinical trialNCT05228600UnknownPhase 1Interventional

YL-13027 in Patients With Advanced Solid Tumors

SponsorShanghai YingLi Pharmaceutical Co. Ltd.Enrollment54Solid Tumor

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Part 1 (Phase Ia): This is a dose escalation, 3 + 3 design study, to evaluate the safety and tolerability, and to determine the RP2D of YL-13027 when administered b.i.d. in patients with advanced solid tumors. Up to 4 cohorts of 3-6 patients each will be treated in part 1 of the study. One cycle is 28 days. Part 2: This is a dose expansion phase to further evaluate the safety, tolerability and preliminary anti-tumor activity of YL-13027 at the RP2D.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Ignacio Ga Laguna,, MD, Ph.D
Huntsman Cancer Institute Salt Lake City, UT 84112
Principal Investigator
clinicaltrials.gov ↗
Jordi Ah Rodon, Ph D
MD Anderson Cancer Center Houston TX 77030
Principal Investigator
clinicaltrials.gov ↗
Martin E Gutierrez, MD
Hackensack University Medical Center Hackensack, NJ 07601
Principal Investigator
clinicaltrials.gov ↗
Trisha Wi Draper, Ph D
University of Cincinnati Cincinnati, OH 45267-0562
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Md Anderson Cancer Center
Houston, Texas, United States
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

YL-13027

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 17 May 2022
Primary completion: 30 Dec 2022
Completion: 1 Dec 2023
Last update posted: 20 May 2022
Registered enrollment: 54
Registry id: NCT05228600

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.